Hexahydrocurcumin
Hexahydrocurcumin has in vitro antioxidant and anti-inflammatory activities, it has potential beneficial effects as a food and/or dietary supplement. Hexahydrocurcumin has cytotoxic effect, may prove useful in cancer prevention, it together with 5-fluorouracil exerts a synergistic effect and may prove chemotherapeutically useful in treating human colon cancer. Hexahydrocurcumin is also an anti-atherosclerogenic agent in humans, can inhibit platelet aggregation in the treatment of human platelet-rich plasma.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Food Chem.2019, 290:286-294
Chem Res Toxicol.2023, 36(2):213-229.
J Agric Food Chem.2024, acs.jafc.4c01387.
Hindawi J of Food Biochemistry2023, P17:8883860
J Nat Prod.2022, doi: 10.1021
Molecules.2023, 28(4):1526.
Food Chem.2024, 446:138870.
Int J Mol Sci.2019, 20(23):E6071
Pharmaceuticals (Basel). 2021, 14(10):986.
Photodermatol Photoimmunol Photomed.2024, 40(1):e12950.
Related and Featured Products
Food Chem. 2012 Nov 15;135(2):332-7.
In vitro antioxidant and anti-inflammatory activities of 1-dehydro-[6]-gingerdione, 6-shogaol, 6-dehydroshogaol and hexahydrocurcumin.[Pubmed:
22868095]
Hexahydrocurcumin, 1-dehydro-[6]-gingerdione, 6-dehydroshogaol and 6-shogaol were evaluated for their antioxidant and anti-inflammatory activities in the present study.
METHODS AND RESULTS:
The relative antioxidant potencies of ginger compounds decreased in similar order of 1-dehydro-[6]-gingerdione, Hexahydrocurcumin>6-shogaol>6-dehydroshogaol in both 1,1-diphenyl-2-picyrlhydrazyl (DPPH) radical-scavenging and trolox equivalent antioxidant capacity (TEAC) assays. All tested compounds could attenuate lipopolysaccharide (LPS)-elicited increase of prostaglandin E2 (PGE(2)) in murine macrophages (RAW 264.7) in a concentration-dependent manner but Hexahydrocurcumin of 7μM and 6-shogaol of 7μM. The strongest inhibitory effect was observed for 6-dehydroshogaol and 6-shogaol at 14μM with the inhibition of 53.3% and 48.9%, respectively. Furthermore, both 6-dehydroshogaol and 1-dehydro-[6]-gingerdione significantly suppressed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins in a concentration-dependent fashion.
CONCLUSIONS:
These results contribute to our theoretical understanding of the potential beneficial effects of consuming ginger as a food and/or dietary supplement.
Nat Prod Commun. 2012 Jul;7(7):883-4.
Inhibitory effect of hexahydrocurcumin on human platelet aggregation.[Pubmed:
22908571]
The effects of Hexahydrocurcumin on adenosine diphosphate (ADP)-induced human platelet aggregation were studied.
METHODS AND RESULTS:
Treatment of human platelet-rich plasma with Hexahydrocurcumin resulted in an inhibitory effect on platelet aggregation, suggesting the potential of this compound as an anti-atherosclerogenic agent in humans.
Nat Prod Commun. 2011 Nov;6(11):1671-2.
Cytotoxic activity and cell cycle analysis of hexahydrocurcumin on SW 480 human colorectal cancer cells.[Pubmed:
22224285]
The cytotoxicity of Hexahydrocurcumin and its effect on the cell cycle in human colorectal cancer cells SW480 has been studied for the first time.
METHODS AND RESULTS:
The compound, extracted from Zingiber officinale, was shown to be cytotoxic to colorectal cancer cells. Treatment of SW480 cells with Hexahydrocurcumin (100 microM) resulted in a massive accumulation of the cells in the G1/G0 phase of the cell cycle.
CONCLUSIONS:
The cytotoxic effect of Hexahydrocurcumin may prove useful in cancer prevention.
World J Gastroenterol. 2012 May 21;18(19):2383-9.
Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells.[Pubmed:
22654430]
To investigate the ability of Hexahydrocurcumin (HHC) to enhance 5-fluorouracil (5-FU) in inhibiting the growth of HT-29 cells by focusing on cyclooxygenase (COX)-2 expression.
METHODS AND RESULTS:
MTT reduction assay indicated that Hexahydrocurcumin alone markedly decreased the viability of HT-29 human colon cancer cells compared to control. Semi-quantitative RT-PCR analysis indicated that Hexahydrocurcumin is a selective COX-2 inhibitor. This finding was supported by the observation that Hexahydrocurcumin significantly down-regulates COX-2 mRNA expression compared to the control (control: 100.05% ± 0.03% vs Hexahydrocurcumin: 61.01% ± 0.35%, P < 0.05) but does not alter COX-1 mRNA. In combined treatment, addition of Hexahydrocurcumin to a low dose of 5-FU exerts a synergistic effect against the growth of HT-29 cells by markedly reducing cell viability to a greater degree than monotherapy. Semi-quantitative RT-PCR indicated that 5-FU at the concentration of 5 μmol/L in combination with Hexahydrocurcumin at the concentration of 25 μmol/L significantly down-regulates COX-2 mRNA expression when compared with values in cells treated with 5-FU or Hexahydrocurcumin alone (Hexahydrocurcumin + 5-FU: 31.93% ± 5.69%, 5-FU: 100.66% ± 4.52% vs Hexahydrocurcumin: 61.01% ± 0.35%, P < 0.05).
CONCLUSIONS:
Hexahydrocurcumin together with 5-FU exerts a synergistic effect and may prove chemotherapeutically useful in treating human colon cancer.
